Menu Search
Equities

Inventionmed SA

INM:WSE

Inventionmed SA

Actions
  • Price (PLN)0.201
  • Today's Change0.00 / 0.00%
  • Shares traded44.98k
  • 1 Year change-12.23%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in PLNIncome statement in PLNView more

Year on year Inventionmed SA had revenues fall -85.01% from 4.07k to 610.00, though the company grew net income from a loss of 22.15m to a smaller loss of 1.89m.
Gross margin-132.80%
Net profit margin-8,979.19%
Operating margin-5,850.98%
Return on assets-11.49%
Return on equity-69.64%
Return on investment-19.50%
More ▼

Cash flow in PLNView more

In 2023, cash reserves at Inventionmed SA fell by 3.95m. Cash Flow from Financing totalled 10.83m or 1,775,495.08% of revenues. In addition the company generated 419.04k in cash from operations while cash used for investing totalled 15.20m.
Cash flow per share-0.0133
Price/Cash flow per share--
Book value per share0.0194
Tangible book value per share0.0187
More ▼

Balance sheet in PLNView more

Inventionmed SA uses little or no debt in its capital structure.
Current ratio0.0288
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.